BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dehbozorghi S, Bagheri S, Moradi K, Shokraee K, Mohammadi MR, Akhondzadeh S. Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci 2019;73:690-6. [PMID: 31294924 DOI: 10.1111/pcn.12913] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Saito T, Yamashita Y, Tomoda A, Okada T, Umeuchi H, Iwamori S, Shinoda S, Mizuno-Yasuhira A, Urano H, Nishino I, Saito K. Using the drug repositioning approach to develop a novel therapy, tipepidine hibenzate sustained-release tablet (TS-141), for children and adolescents with attention-deficit/hyperactivity disorder. BMC Psychiatry 2020;20:530. [PMID: 33167920 DOI: 10.1186/s12888-020-02932-2] [Reference Citation Analysis]
2 Ren Y, Fang X, Fang H, Pang G, Cai J, Wang S, Ke X. Predicting the Adult Clinical and Academic Outcomes in Boys With ADHD: A 7- to 10-Year Follow-Up Study in China. Front Pediatr 2021;9:634633. [PMID: 34408992 DOI: 10.3389/fped.2021.634633] [Reference Citation Analysis]
3 Ayatollahi A, Bagheri S, Ashraf-ganjouei A, Moradi K, Mohammadi M, Akhondzadeh S. Does Pregnenolone Adjunct to Risperidone Ameliorate Irritable Behavior in Adolescents With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial? Clin Neuropharm 2020;43:139-45. [DOI: 10.1097/wnf.0000000000000405] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther 2021;:107940. [PMID: 34174276 DOI: 10.1016/j.pharmthera.2021.107940] [Reference Citation Analysis]
5 Hoobehfekr S, Moghaddam HS, Shalbafan M, Hashemi MG, Pirmoradi MM, Sakenian A, Poopak A, Kashefinejad S, Yarahmadi M, Akhondzadeh S. Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci 2021;75:57-62. [PMID: 33247483 DOI: 10.1111/pcn.13180] [Reference Citation Analysis]
6 Rafeiy-Torghabeh M, Ashraf-Ganjouei A, Moradi K, Bagheri S, Mohammadi MR, Akhondzadeh S. Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. Eur Child Adolesc Psychiatry 2021;30:799-807. [PMID: 32449130 DOI: 10.1007/s00787-020-01562-z] [Reference Citation Analysis]
7 Pozzi M, Bertella S, Gatti E, Peeters GGAM, Carnovale C, Zambrano S, Nobile M. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs 2020;25:395-407. [PMID: 32938246 DOI: 10.1080/14728214.2020.1820481] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cortese S, Newcorn JH, Coghill D. A Practical, Evidence-informed Approach to Managing Stimulant-Refractory Attention Deficit Hyperactivity Disorder (ADHD). CNS Drugs 2021. [PMID: 34403134 DOI: 10.1007/s40263-021-00848-3] [Reference Citation Analysis]